A new public–private research consortium aiming to advance precision cancer treatment has been awarded €14.9 million in funding from the EU’s Innovative Health Initiative (IHI).
The PreciseOnco research consortium, coordinated by Philips, was created as a five-year research program to advance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies.
An additional €9 million in "in-kind" contributions from partners in the industry will supplement the IHI funding, the consortium said.
The total budget of €23.9 million will be used to fund the research program, which will include five clinical studies for validating technical advances such as spectral imaging, robotic guidance, and electrochemotherapy, as well as creating a suite of AI-guided integrated technologies for precision cancer care.
PreciseOnco members include industry partners (Philips, Quantum Surgical, IGEA), the European Institute for Biomedical Imaging Research (EIBIR), the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and several academic institutions -- University Hospital Cologne (Uniklinik Koeln) in Germany, University Medical Center Utrecht (UMCU) and Leiden University Medical Center (LUMC) in the Netherlands, along with two major university hospital networks in France: Assistance Publique-Hôpitaux de Paris (APHP; Hôpital Henri-Mondor) and Hospices Civils de Lyon (HCL).
